DYVE BIOSCIENCES

Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery. The company is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary science. Dyve’s most advanced asset, DYV-700, is in phase 2 for the treatment of acute gout using a mechanism of action enabled by Dyve’s science. The company has PK data demonstrating injection-like delivery across a broad range of molecules. It was founded in 2014 and is headquartered in Thousand Oaks, California.